HGF-induced MET activation could confer resistance to cetuximab in CRC cells.MET amplification is associated with primary resistance to cetuximab in CRC patient-derived tumor xenografts. MET amplification is associated to acquired resistance to cetuximab or panitumumab in mCRC patients. This evidence concerns the gene MET and neoplasm.